Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I have been monitoring the number of “Likes” the Covidity advert is receiving. At the time of this post it has 46 “Likes”; this is the link to the advert:-
https://lunginstitute.co.za/2022/05/25/covidity-research-participants-needed/
These are the facts:-
Date Number of “likes”
Saturday 25 June 30
Saturday 2 July 37
Saturday 9 July 40
Saturday 16 July 40
Saturday 23 July 41
Monday 25 July 42
Friday 29 July 43
Friday 5 August 44
Monday 8 August 45
Friday 12 August 46
Initially I was just looking weekly on a Saturday, but then a pattern emerged. I noticed that the advert now tends to get two “likes” a week, one on Mondays and one on Fridays.
This is the speculation:- I believe that there is a direct correlation between the number of patients being dosed and the number of “likes” and that this demonstrates that the trial is steadily progressing. It is a possibility that after each patient has received their second dose of SCOV2 (or 1st and only dose if they have previously been infected) and later attends their final end of study assessment the Lung Institute staff ask them, if they are happy, to “like” the Covidity advert.
If I am right the advert should receive another “like” on Monday (with the caveat that the patient has internet access).
I realise that this is totally inconclusive as anyone, not just patients, could “like” the advert. Nevertheless I thought that it was worth mentioning.
JB1 - an interesting theory, although I suspect it doesn’t tie together as you think it might. As a for instance, I’ve “liked” the advert and no doubt so have other SCLP’ers. Can’t remember what day of the week it was :-)
What I’d like to know is where else that ad is being promoted, if anywhere. If just on the SA Lung Institute site, then not going to be seen by many. Maybe there are some ethical restrictions around that, that I don’t understand.
Apologies for enquiring about something apparently well known: Where is this advert?
I'd like to see it for myself - I might even like it
Hi LochinvarLass,
It is on the University of Cape Town Lung Institute web site. If you click on the link in my earlier post it should take you there. Here it is again:-
https://lunginstitute.co.za/2022/05/25/covidity-research-participants-needed/
Thanks for coming back to me about the link.
I saw the page with the advert, but i couldn't see anything about likes.
All the best f9r the weekend
LL,
On the first page, top left there is a heart under the institute logo. Click that to like.
For goodness sake as nobody read the article in Bloomberg that I posted this morning https://www.bloomberg.com/news/articles/2022-08-10/pfizer-pfe-biontech-bntx-aim-to-preserve-immunity-with-pan-coronavirus-shot morning which is very clear that in Jean Pfizer and bio realised that the booster jab from chrome was gonna be useless are you go who do we https://www.bloomberg.com/news/articles/2022-08-10/pfizer-pfe-biontech-bntx-aim-to-preserve-immunity-with-pan-coronavirus-shot know that has a vaccine that is actually variant proof who do we know that has a collaboration agreement with Scancell my own tech? I am not sure I just think that this is the best bet to partner with Scancell to produce a pain vaccine also biotech CEO stated that they want to be the leader for Covid vaccines hello https://www.bloomberg.com/news/articles/2022-08-10/pfizer-pfe-biontech-bntx-aim-to-preserve-immunity-with-pan-coronavirus-shot I am not sure I just think that this is the best bet to partner with Scancell to produce a pain vaccine also biotech CEO stated that they want to be the leader for Covid vaccines hello https://www.bloomberg.com/news/articles/2022-08-10/pfizer-pfe-biontech-bntx-aim-to-preserve-immunity-with-pan-coronavirus-shot
Sorry I didn’t edit the last post before I sent it was full of typos . I kept getting distracted. The main point is Fauci not interested in the latest version of Biontech/ Pfizer omicron variant vaccine in the Autum because the virus will once again have changed , . So in June they had to go back to the lab and find a variant proof vaccine ?
Or who of their collaborative pharma science was already working on such a thing ?
That's an eye opening article on Bloomberg @cleanerworld, it has somewhat answered my question RE weather mRNA vaccines could work as pan universal vaccine:
"“Even with the highly flexible platform of mRNA, which is more flexible than virtually anything we’ve had before, it’s going to be very difficult to keep up with the pace of newly evolving variants,” Fauci said in an interview. “Which gets us to the question: What about a pan-coronavirus vaccine?”
And also :
Secret Sauce’
Pfizer’s leaders had earlier suggested that they weren't focusing on development of an all-encompassing shot. But laboratory evidence has raised the stakes. In June, Pfizer and BioNTech research showed their bivalent omicron-adapted vaccine candidates neutralized BA.4 and BA.5, though to a lesser extent than the original omicron variant, BA.1, prompting the Biden administration to ask for shots that were focused on the newer subvariants.
Cleaner/ WTP - I recently read about that new Pfizer/BioNTech vax - it seemed to focus on wider coverage of 'Omicron' only. What puzzles me - there is a close relationship between BioNTech and Scancell - they know what Covidity is about. With the importance of Covid in mind I would have expected BioNTech to get involved. I mean, there's no time to lose on this front is there? Maybe the BioNTech powers that be don't rate the Covidity project or they feel the 'nih' factor - (not invented here).
Let's hope we get an update soon . . .
Is there any relationship between Scancell and BioNTech anymore. The collaboration was announced in January 2018, since which time there have been few if any updates.
The last Trinity Delta report mentions BioNTech once only, describing them as a competitor and "prior collaborator"
Things have changed significantly since 2018 so It would be good to clarify the exact nature of any relationship if any before getting too carried away.
Yes TF, I was thinking the same. Who know's still may happen.
Obviously BionTech will be fully aware of Covidity, how interested they are, if at all, is a key question.
But despite BionTech and Pfziers huge wealth, size, ability to upscale etc. they would (IMO) still have somewhat of a headstart and DNA vaccine expertise if they decided to partner with Scancell.
The link between Scancell and Biontech is well known, but I would imagine and tie-up in respect of covidity would wait until at least the phase 1 results are assembled and reviewed. There are, imo, very reasonable grounds for optimism that such a tie-up is a realistic possibility, but just for balance it might be that the sp is about to drop by 60 percent or more. (No basis for that last comment, it's just to keep certain quarters from having to expend energy stirring fiction on a hot Sunday)
Hi TF/RR,
As you say still a few unanswered questions like what is exact nature of Bion Tech/SCLP which was based in TCRs but we know personal relationships is good.
I remember RG telling me that whilst major pharma readily understood DNA platforms they did not not always comprehend the complexity of newer approaches like Moditope so what we don’t know how what the reverse is ie Bion Tech familiarity and acceptance of DNA Platforms.
We know that SCLP developed Covidity completely seperately to any input from Bion Tech.We also know that the Bion Tech/Pfizer arrangement was a much wider potential co- operation than Covid 19 Vax.It was a way of testing mRNA technology in an infectious disease setting and getting Approval hence generating huge amounts of data and knowledge primarily for Pfizer.In fact at one stage the fact was that Pfizer would abandon Bion Tech and just develop the platforms themselves,something that seems to have changed.
Also don’t forget the need for the collaboration.
Pfizer needed Bion Tech to provide the creativity to develop the Vaccine and then Pfizer would provide the manu,distribution etc to complete the process.
The situation with SCLP is entirely different as it is an SCLP Vax and they have done all the science and creativity in developing Vax so the type of partner they need is someone who can manu the Vax which is very specialised and then use their existing logistics set up to distribute the Vax and finance through the regulatory process.
I really don’t think that is Bion Techs game and not even sure if they have Vax manu facilities.Most manu capacity is already fixed and set up years ahead and production is very specialised and long lead times.
So whilst I understand all the logic of a universal Covid Vax rather than simply adding a valency for a new variant this is about so much more than the science and the choice of a partner is limited.
Ratty,
"The link between Scancell and Biontech is well known"
Well it was well reported in 2018 and so I guess at the time "well known"
But why have there been no updates since then? The area of interest was Moditope so it may be that progress is dependent on trial data, who knows?
But why do TD describe BioNtech as a "competitor" and "PRIOR collaborator" (capitals added). Prior suggests that the collobaration ended at some point. If it has, then it wasn't reported. This then puts into question other collaborations - are these active, dormant or terminated. It would be good to know these things.
So ratty, if you could address any of the questions sensibly it would be appreciated.
A Google search of 'scancell biontech' yields result showing an association
https://www.google.co.uk/search?q=scancell+biontech&source=hp&ei=vM74YpubNsKT8gLPs4fYBQ&oq=scancell+biontech&gs_lcp=ChFtb2JpbGUtZ3dzLXdpei1ocBADMgYIABAeEBYyBQghEKABMgUIIRCgATIFCCEQoAE6CAgAEI8BEOoCOggILhCxAxCDAToRCC4QgAQQsQMQgwEQxwEQ0QM6CwgAEIAEELEDEIMBOg4ILhCABBCxAxDHARDRAzoICAAQgAQQsQM6BQgAEIAEOgsILhCxAxCDARDUAjoICAAQsQMQgwE6CwguEIAEELEDEIMBOggILhCABBCxAzoFCC4QgAQ6EQguEIAEELEDEIMBEMcBEK8BOgoIABCABBBGEPoBOgsILhCABBDHARDRAzoKCAAQHhAPEBYQCjoICAAQHhAPEBY6BQgAEIYDOgcIIRCgARAKUMQIWIA9YO9GaAFwAHgAgAG_AYgB2Q6SAQQ3LjEwmAEAoAEBsAEP&sclient=mobile-gws-wiz-hp
The association can imo be called 'Well known' on this board, but as usual the extent and activity relating to it is anyone's guess, so please don't jump down my throat and try to suggest my post implies anything imminent or bolted on re Biontech. PRIOR collaborations would be covered by the Grand Challenge project blueprint, but again it depends how a poster wants to interpret PRIOR. Former and now defunct, or previously engaged upon and out of the limelight? I don't think the words 'very reasonable grounds for optimism that such a tie-up is a realistic possibility' are too much in the forbidden realm of happy clappy mad ramper buy buy buy eight quid a share though.
Ruck - I thought I had raised the point quietly enough. I'm not getting 'carried away' ! But I hadn't noticed TD describing BioNTech as a 'prior collaborator' and that's interesting and maybe a little disappointing.
Ivy thanks - Cleaner's link shows that BioNTech do some manufacturing. In their relationship with Pfizer, I'd be surprised if BioNTech were not at least controlling the manufacture as part of their deal simply because BioNTech are the masters of the science for that vax.
We'll see - news coming ! But so is Christmas . . . . .
Ruck - interesting, I had missed that.
I understood that Scancell hadn't been able to create suitable Modi1 TCRs in the lab, but were hopeful that when the Modi1 trial was underway they may be more successful when using blood from vaccinated patients. Given that the collaboration with BioNTech gave them an exlusive option to license Modi1 TCRs, it's seems perfectly sensible that the agreement wasn't open ended and just allowed to run ad infinitum. I'm sure if/when Scancell do produce promising candidates then they'll resume discussions with BioNTech and I'm equally sure that BioNTech will be keeping a watching eye on how Modi1 performs in the clinic.
As for Covidity, I know it won't be a popular opinion here, but I can't see any involvement from BioNTech - it simply doesn't fit in with their strategy. BioNTech is an mRNA pioneer, it's the very essence of the Company. Of course I may be wrong but I just don't see why they would deviate from that path and switch to a DNA vaccine. The most likely candidate for a partner for Covidity (assuming positive trial results) is one of the big biotechs or perhaps smaller pharmas who have missed the boat with 1st/2nd generation covid vaccines and are looking for a vaccine platform that can be quickly adapted to also target other infectious diseases.
If Covidity went no further, it will still have been hugely beneficial to Scancell and their shareholders. ImmunoBody comes out the other side with an extended patent life, a new improved delivery method and enhanced efficacy (assuming successful results) and Avidimab gets its first in human trial - all achieved through non-dilutive funding. Moreover, covid has triggered a resurgence in the field of vaccines and interest in cancer vaccines.
All IMO
What I find most interesting is that the current Biontech / Pfizer offering is not dynamic enough moving forward . The gravy booster train is stuck in the station . Waiting for the next generation vaccine . Scancell are in the clinic already . Bermuda did you read the Bloomberg post .
Yes I did - intriguing and looking forward to finding out exactly what they're developing when they're in a positiion to go public.
Thanks Bermuda. Fairly put but if BioNTech can observe that there is better science and a better potential vax product available, I am quite certain that it is a possibility that they, or any other Company for that matter, might consider changing strategy IF the advantages of doing so were obvious enough. I'd also think Pfizer might jump with them IF the data was good enough.
The stakes for a possibly more universal Covid vax are the very highest. I'm not getting carried away (Ruck), but it is a possibility.
I enjoyed your comments about how much the Covidity research has helped the wider Scancell cause.
ATB
It also highlights how little competition there is for covidity as a universal vaccine.
Please Scancell can we have an update!